UBRELVY PHARMACOKINETIC CHARACTERISTICS

Efficacy

When it comes to migraine treatment,
the proof is in the data

Choose UBRELVY® for a migraine treatment that is rapid, powerful, and proven1,2

Explore how UBRELVY can help patients manage migraine pain.

RAPID

Quick pain relief1

POWERFUL

Zero pain, sustained1,2

PROVEN

Well established in market2

RAPID

QUICK PAIN RELIEF

RETURN TO FUNCTION

A majority of patients achieved normal function at 2, 4, and 8 hours2

Additional endpoint: Percentage of patients achieving normal function* at 2, 4, and 8 hours with a single dose2†

A majority of patients achieved normal function over 2 to 8 hoursA majority of patients achieved normal function over 2 to 8 hours

Limitation: The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity. Results could represent chance findings.

UBRELVY HELPED THE MAJORITY OF PATIENTS GET BACK TO NORMAL FUNCTION2

  • At 2 hours, 64% (100 mg; 125/196) and 60% (50 mg; 228/383) of patients taking UBRELVY achieved normal function compared with 54% (139/258) taking placebo2
  • At 4 hours, 81% (100 mg; 158/196) and 77% (50 mg; 295/383) of patients taking UBRELVY achieved normal function compared with 67% (172/258) taking placebo2
  • At 8 hours, 91% (100 mg; 179/196) and 87% (50 mg; 334/384) of patients taking UBRELVY achieved normal function compared with 76% (195/258) taking placebo2

Limitation: The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity.

*Patients were asked to rate the performance of daily activities using 4 response options ranging from 0 (no disability, able to function normally) to 3 (severely
impaired, cannot do all or most things, bed rest may be necessary).2

Data collected after rescue medication or second dose was excluded.2

UBRELVY 100 mg was included only in ACHIEVE I.1

UBRELVY WORKS DIFFERENTLY

UBRELVY works differently

UBRELVY is the first acute treatment for migraine to directly block calcitonin gene-related peptide (CGRP).6

PROVEN

Well established in market

UBRELVY CONTINUES TO BE THE MOST PRESCRIBED BRANDED TREATMENT FOR MIGRAINE ATTACKS1,10

Since approval, UBRELVY is most prescribed in its class11

77,000+ prescribing physicians2
500,000+ treated patients2
2+ million prescriptions2

As of 10/22.

Ubrelvyhcp efficacy separator

Every patient is different—UBRELVY studies included a diverse patient population,
including those with1,2:

Every patient is
different—UBRELVY studies
included a diverse patient
population, including those
with1,2:

PRIOR TRIPTAN USE

PRIOR
TRIPTAN USE

CONCOMITANT PREVENTIVE USE

CONCOMITANT
PREVENTIVE USE

HISTORY OF DEPRESSION

HISTORY OF
DEPRESSION

HISTORY OF ANXIETY

HISTORY OF
ANXIETY

CARDIOVASCULAR RISK

CARDIOVASCULAR
RISK

Up next: Learn about the
safety of UBRELVY